“Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the excessive accumulation of extracellular matrix components, leading to declining lung function and ultimately respiratory failure.”
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease that primarily affects people over the age of 60. It causes scarring in the lung tissue, which gradually reduces lung capacity and makes breathing difficult. Despite years of research, the exact causes of IPF remain largely unknown, and current treatments mainly aim to slow its progression rather than reverse or cure the disease.
Because IPF tends to develop later in life, researchers have long suspected a connection with biological aging. This is the focus of a recent study by scientists from Insilico Medicine. Their research, titled “AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging,” was published recently in Aging-US, Volume 17, Issue 8.
The Study: Using AI to Explore the Link Between IPF and Aging
To investigate the biological relationship between IPF and aging, researchers Fedor Galkin, Shan Chen, Alex Aliper, Alex Zhavoronkov, and Feng Ren, from Insilico Medicine, developed two artificial intelligence (AI) tools. The first, a proteomic aging clock, estimates a person’s biological age using protein markers found in blood samples. The second, a specialized deep learning model named ipf-P3GPT, was trained to analyze patterns of gene activity in both normal aging and fibrotic lung tissue.
The aim was to explore whether IPF mirrors biological aging or whether it follows a separate disease pathway. While aging and IPF share common features, such as chronic inflammation and tissue damage, it is not yet clear if IPF is simply accelerated aging or a distinct biological process. Distinguishing between the two is essential for developing more targeted and effective treatments.
To train the aging clock, the team used the UK Biobank collection of over 55,000 proteomic Olink NPX profiles, annotated with age and gender. They then applied the model to patients with severe COVID-19, a population known to be at higher risk of developing lung fibrosis. In parallel, the ipf-P3GPT model simulated and analyzed gene expression patterns in lung tissue, allowing the team to directly compare the biological signatures of aging and IPF.
Results: IPF and Aging Are Distinct Biological Entities
The aging clock accurately estimated biological age in healthy individuals. When applied to patients with severe COVID-19, the clock predicted higher biological ages compared to healthy controls. This finding suggests that fibrotic lung conditions may be linked to accelerated biological aging and that such changes leave a detectable molecular signature in the body.
Using the ipf-P3GPT model, the researchers found that while 15 genes were shared between lung tissue affected by normal aging and IPF, more than half of these genes displayed opposite patterns of activity, being upregulated in aging but downregulated in IPF, or vice versa. These results indicate that IPF is not merely a faster version of aging but a distinct biological condition influenced by age-related dysfunction and unique molecular alterations.
The Impact: Toward Better Understanding and Treatment of Fibrotic Diseases
A key insight from this study is that although aging and IPF are biologically related, they follow different molecular pathways. IPF involves changes in gene expression and tissue remodeling that go beyond the patterns typically seen in normal aging. This difference could guide the development of therapies that specifically target fibrosis without interfering with healthy aging processes.
The AI tools developed in this research also have broader potential. The aging clock could be used to identify individuals whose biological age is advancing more quickly due to hidden disease processes, even before symptoms appear. At the same time, ipf-P3GPT provides a framework for studying how aging and disease interact on a molecular level, which could be applied to other age-related or fibrotic conditions such as liver or kidney fibrosis.
By combining AI with large-scale biological data, this approach introduces a powerful toolset that supports more personalized treatment strategies and a better understanding of age-related disease mechanisms.
Future Perspectives and Conclusion
While the results are promising, further validation is needed. Both models should be tested across diverse patient datasets and clinical settings to confirm their reliability and usefulness. Still, this study highlights how AI can support medical research by uncovering subtle biological differences between aging and disease.
Overall, this study establishes novel connections between IPF disease and aging biology while demonstrating the potential of AI-guided approaches in therapeutic development for age-related diseases. By helping scientists better understand where aging ends and disease begins, these AI tools may contribute to earlier diagnosis, more accurate monitoring, and improved treatment strategies for patients facing fibrotic and age-related conditions.
Click here to read the full research paper published in Aging-US.
___
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Click here to subscribe to Aging publication updates.
For media inquiries, please contact [email protected].